January 1, 2004Cerebrovascular Diseases
Ongoing and Planned Trials of Antiplatelet Therapy in the Acute and Long-Term Management of Patients with Ischaemic Brain Syndromes: Setting a New Standard of Care
Why the study?
Does combination antiplatelet therapy reduce serious vascular events in patients with ischaemic brain syndromes compared to monotherapy?
Population
Patients with ischaemic brain syndromes (TIA, acute ischaemic stroke) and high vascular risk patients
Comparison
Combination antiplatelet therapy vs Monotherapy (e.g., ASA alone) or placebo
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Combination antiplatelet therapy remains unproven for ischaemic brain syndromes; leaves open net benefit versus monotherapy until MATCH and CHARISMA report.
Structured PICO
Does combination antiplatelet therapy reduce serious vascular events in patients with ischaemic brain syndromes compared to monotherapy?
P
Population
Patients with ischaemic brain syndromes (TIA, acute ischaemic stroke) and high vascular risk patients
I
Intervention
Combination antiplatelet therapy (e.g., ASA + clopidogrel, ASA + GP IIb/IIIa blocker, ASA + dipyridamole)
C
Comparator
Monotherapy (e.g., ASA alone) or placebo
O
Outcome
Serious vascular eventshard clinical
Ongoing clinical trials will further define the efficacy and safety of combination antiplatelet therapies in the management of ischaemic brain syndromes.
Cite This Study
Graeme J. Hankey (2004) studied this question.